Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profile...

Full description

Bibliographic Details
Main Authors: Walid Shalata, Jeremy Zolnoorian, Gabrielle Migliozzi, Ashraf Abu Jama, Yulia Dudnik, Ahron Yehonatan Cohen, Amichay Meirovitz, Alexander Yakobson
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
pembrolizumab
Keytruda
lung cancer
non-small cell lung cancer
PD-1
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/1422-0067/24/6/5938

Internet

https://www.mdpi.com/1422-0067/24/6/5938

Similar Items